A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer

Trial Profile

A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Ceritinib (Primary) ; Luminespib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 08 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
    • 08 Jan 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top